## MRK: Merck & Co., Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%); PEG 1.12 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($95.47)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)**
- Source: PharmiWeb.com | 20251204T201330 | Bullish | Relevance: 100%
- The FDA has granted conditional approval to Merck Animal Health's EXZOLT™ CATTLE-CA1 (fluralaner topical solution) for the prevention and treatment of New World screwworm and treatment and control of cattle fever tick. This is the first ectoparasiticide for beef cattle in decades and allows veterinarians and cattle producers a new tool to protect livestock from these parasites. EXZOLT™ CATTLE-CA1 is approved for beef cattle two months and older and replacement dairy heifers under 20 months, with a 98-day meat withdrawal period.

**2. Merck (NYSE: MRK) gets FDA conditional OK for EXZOLT CATTLE-CA1 vs New World screwworm**
- Source: Stock Titan | 20251204T170807 | Bullish | Relevance: 100%
- Merck Animal Health has received conditional FDA approval for EXZOLT™ CATTLE-CA1, an innovative pour-on solution for cattle. This marks the first isoxazoline parasiticide conditionally approved for the prevention and treatment of New World screwworm larvae and control of cattle fever ticks. The product addresses a significant threat to U.S. agriculture and will be available by prescription in early 2026.

**3. Merck & Co., Inc. at the Citi 2025 Global Healthcare Conference**
- Source: Merck.com | 20251203T130000 | Neutral | Relevance: 100%
- Merck & Co., Inc. announced its participation in the Citi 2025 Global Healthcare Conference, scheduled for December 3, 2025, at 1:00 p.m. EST. The company provides details for adding the event to various calendars and contact information for investor inquiries. Key investor resources, including financial information, stock data, and investor services, are also highlighted.

**4. The Goldman Sachs Group Boosts Merck & Co., Inc. (NYSE:MRK) Price Target to $120.00**
- Source: MarketBeat | 20251202T184051 | Somewhat-Bullish | Relevance: 100%
- The Goldman Sachs Group raised its price target for Merck & Co., Inc. (NYSE:MRK) to $120.00 from $92.00, maintaining a "buy" rating and indicating a potential upside of 19.17%. The company recently reported an EPS beat and provided FY2025 guidance. This update comes amidst various analyst ratings, with the consensus remaining a "Moderate Buy" with an average price target of $107.82.

**5. The American biopharm company Merck plans to raise $8 billion through the sale of bonds**
- Source: AKM.RU | 20251202T183500 | Somewhat-Bullish | Relevance: 100%
- Merck&Co Inc. plans to raise $8 billion through the sale of corporate bonds to finance its acquisition of Cidara Therapeutics Inc., and for other purposes, including debt repayment. This bond sale, organized by several major banks, will be split into 8 tranches with maturities from three to 40 years. This move follows Merck's recent acquisition of Cidara Therapeutics for $9.2 billion and Verona Pharma Plc for $10 billion, as the company seeks to expand its drug portfolio in anticipation of significant patent expirations.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 1.12 suggests fair value with growth premium. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $266.7B |
| Beta | 0.30 |
| 52W Range | $73.31 - $107.04 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.12 |
| Forward P/E | 12.2 |
| Current P/E | 11.2 |
| YoY Growth | -7.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.6% to -2.5% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.46% (CS: 26) | Weak |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.123x | Above |
| vs SMA200 | 1.190x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $100.89
- **Stop Loss:** $95.47 (5.4% risk)
- **Target:** $106.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 92
- **Position Value:** $9,281.88
- **Portfolio %:** 9.28%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*